NCT07321847 2026-01-07
INJECTABL-3
Immunophotonics, Inc.
Phase 2/3 Not yet recruiting
Clinical Trials
9 trialsNCT06788756 2025-12-16
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
Moleculin Biotech, Inc.
Phase 2/3 Recruiting
NCT07165886 2025-09-10
Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2/3 Recruiting
NCT03092674 2025-01-16
Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
National Cancer Institute (NCI)
Phase 2/3 Completed
NCT04209868 2024-03-29
ParaSOL
Guy's and St Thomas' NHS Foundation Trust
Phase 2/3 Recruiting
NCT06282588 2024-02-28
THUNDER
Cancer Research Antwerp
Phase 2/3 Recruiting
NCT05809336 2023-04-12
Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors
Beijing Friendship Hospital
Phase 2/3 Completed
NCT01333293 2016-01-18
XOLMA
University of Zurich
Phase 2/3 Completed
NCT00034333 2005-06-24
Safety and Efficacy of Doxorubicin Adsorbed to Magnetic Beads Vs. IV Doxorubicin in Treating Liver Cancer
FeRx
Phase 2/3 Terminated